logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Stephen Norris

This inventor holds 20 USPTO granted patents and 5 published patent applications and 5 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Celgene Corporation, Signal Pharmaceuticals, Inc.. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stephen Norris. Retrieved from https://idiyas.com/inventor/stephen-norris

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 20 

% Patents Active = 100.0

 

Average Co-Inventor Count = 15.0

ph-index = 6

Forward Citations = 171(Granted Patents)


Company Filing History:

goldMedal10 out of 561 
 
Celgene Corporation
 patents
silverMedal10 out of 169 
 
Signal Pharmaceuticals, Inc.
 patents

Years Active: 2015-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Cereblon Binding Compounds
Diaminopyrimidyl Compounds
Pyrimidines
Aminophenyl Compounds
Compositions
Methods of Treatment
Diaminocarboxamide
Amino Compounds
Pharmaceuticals
Therapeutics
20 patents (USPTO):Explore Patents
1. 12734170 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2026-09-15),
2. 12404241 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2025-09-02),
3. 12227490 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2025-02-18),
4. 12129237 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith (2024-10-29),
5. 12103920 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2024-10-01),
6. 11873283 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2024-01-16),
7. 11739075 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2023-08-29),
8. 11634407 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2023-04-25),
9. 11560371 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2023-01-24),
10. 11325890 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith (2022-05-10),
11. 11325889 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2022-05-10),
12. 11149007 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2021-10-19),
13. 10919865 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith (2021-02-16),
14. 10266500 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith (2019-04-23),
15. 10040770 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith (2018-08-07),

Title: The Innovative Contributions of Stephen Norris

Introduction

Stephen Norris, a distinguished inventor based in San Diego, California, has made significant strides in the field of medicinal chemistry. With an impressive portfolio of 18 patents, he has dedicated his career to developing innovative compounds and methods that hold promise in treating various diseases.

Latest Patents

Among his latest contributions, Norris has developed new Cereblon binding compounds, which include piperidine dione compounds. These compounds are designed to provide therapeutic benefits for treating or preventing androgen receptor-mediated diseases. Additionally, he has patented substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, which consist of diaminopyrimidine compounds that exhibit potential for new treatment methodologies.

Career Highlights

Throughout his career, Stephen has worked with prominent companies in the pharmaceutical industry, including Signal Pharmaceuticals and Celgene Corporation. His experience in these innovative environments has enriched his research and understanding of drug development processes, increasing his impact in the field.

Collaborations

Stephen’s innovative journey has also involved collaboration with talented individuals, including colleagues Matthew Daniel Correa and Joshua Hansen. These partnerships exemplify the collaborative nature of scientific research, enabling the exchange of ideas that foster significant advancements in medicinal therapies.

Conclusion

In conclusion, Stephen Norris's contributions to the field of medicine through his patented inventions reflect a deep commitment to improving health outcomes. His work continues to inspire innovation and progress within the pharmaceutical industry, marking him as a key figure in the realm of scientific invention.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…